Literature DB >> 2706638

Synergic action between tumor necrosis factor and endotoxins or poly(A.U) on cultured bovine endothelial cells.

P A van de Wiel1, R H Pieters, A van der Pijl, N Bloksma.   

Abstract

In order to investigate whether direct effects on tumor vasculature may contribute to induction of necrosis of solid tumors in vivo, agents and combinations with an established different capacity to induce tumor necrosis were studied for their effects on endothelial cells in vitro. Tumor necrosis serum caused a marked inhibition of [3H]thymidine incorporation by bovine umbilical cord endothelial cells after 4 h coincubation. Endotoxin was less inhibitory, whereas detoxified endotoxin and recombinant human tumor necrosis factor (rTNF) were hardly active in concentrations that can be achieved in vivo. Combinations of rTNF and (detoxified) endotoxin caused synergic inhibition. By 24 h effects of the separate agents and synergic effects of the combinations were much stronger. The nontoxic dsRNA, poly(A.U), also had inhibitory activity, and acted synergistically with rTNF. Morphologically, a combination of endotoxin and rTNF but not the separate constituents induced marked cell detachment by 24 h, an indication of cell death. Whereas both endotoxin and rTNF inhibited DNA synthesis of human endothelial cells, the agents did not act synergistically on these cells. The ability of the agents and the combinations to affect endothelial cells in culture appeared to be well in line with their capacity to induce tumor necrosis. Data suggest that direct (synergic) effects on endothelium may contribute to the induction of vascular damage in tumors by (combinations of) the agents. The fact that endothelial cell death is only induced by the combinations and not by the separate agents in vivo, may be a cause of the greater therapeutic activity of the combinations in vivo. The synergy between rTNF and the other agents indicates that the agents act by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706638     DOI: 10.1007/BF00199912

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  32 in total

1.  Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers.

Authors:  A H Stolpen; E C Guinan; W Fiers; J S Pober
Journal:  Am J Pathol       Date:  1986-04       Impact factor: 4.307

2.  Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha.

Authors:  S J Leibovich; P J Polverini; H M Shepard; D M Wiseman; V Shively; N Nuseir
Journal:  Nature       Date:  1987 Oct 15-21       Impact factor: 49.962

3.  Combination immunotherapy of cancer in a mouse model: synergism between tumor necrosis factor and other defense systems.

Authors:  M Chun; M K Hoffmann
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

4.  Effects of endotoxin-treatment on inflammatory cell infiltrates in murine Meth A sarcoma.

Authors:  C F Kuper; N Bloksma; J P Bruyntjes; F M Hofhuis; G Wolterink
Journal:  J Pathol       Date:  1985-09       Impact factor: 7.996

5.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.

Authors:  A Asher; J J Mulé; C M Reichert; E Shiloni; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

6.  Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity.

Authors:  P A Van de Wiel; N Bloksma; C F Kuper; F M Hofhuis; J M Willers
Journal:  J Pathol       Date:  1989-01       Impact factor: 7.996

7.  Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo.

Authors:  N Bloksma; C F Kuper; F M Hofhuis; B Benaissa-Trouw; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo.

Authors:  B A Beutler; I W Milsark; A Cerami
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

9.  Vascular endothelium as the vulnerable element in tumours.

Authors:  J Denekamp
Journal:  Acta Radiol Oncol       Date:  1984

10.  Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon.

Authors:  G Trinchieri; M Kobayashi; M Rosen; R Loudon; M Murphy; B Perussia
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more
  5 in total

1.  Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity.

Authors:  P A van de Wiel; A van der Pijl; N Bloksma
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Antibodies to Cowdria ruminantium in Mozambican goats and cattle detected by immunofluorescence using endothelial cell culture antigen.

Authors:  M Asselbergs; F Jongejan; A Langa; L Neves; S Afonso
Journal:  Trop Anim Health Prod       Date:  1993-08       Impact factor: 1.559

3.  Protective immunity to heartwater (Cowdria ruminantium infection) is acquired after vaccination with in vitro-attenuated rickettsiae.

Authors:  F Jongejan
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

4.  Susceptibility of bovine umbilical cord endothelial cells to bovine herpesviruses and pseudocowpox virus.

Authors:  G J Wellenberg; E R A M Verstraten; F Jongejan; J T Van Oirschot
Journal:  Vet Res Commun       Date:  2002-07       Impact factor: 2.459

5.  Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro.

Authors:  B Robaye; R Mosselmans; W Fiers; J E Dumont; P Galand
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.